Hasil Pencarian  ::  Simpan CSV :: Kembali

"Kanker ovarium masih menempati urutan kedua terbanyak dalam keganasan ginekologi dan merupakan penyebab utama kematian akibat kanker pada perempuan. Banyak bukti menunjukkan bahwa kanker ovarium umunya dalam pengaruh stress oksidatif. Dalam penelitian ini bertujuan untuk mengetahui aktivitas stress oksidatif melalui pengukuran enzim Superoxide Dismutase (SOD) dan kadar Malondialdehyde (MDA) pada penderita keganasan ovarium dibandingkan dengan penderita tumor jinak ovarium. Penelitian dilakukan dengan uji potong-lintang yang dilaksanalan di Ruang Rawat Kebidanan Ginekologi RSCM Jakarta, RS Persahabatan Jakarta dan RS Fatmawati Jakarta pada Juli hingga Desember 2018. Seluruh penderita keganasan ovarium dan penderita tumor jinak ovarium yang memenuhi kriteria diikutsertakan dalam penelitian ini. Darah penderita tumor ovarium diambil sebelum dilakukan operasi, lalu sampel dilakukan pengukuran kadar SOD dan MDA. Terdapat 35 penderita keganasan ovarium dan 43 penderita tumor jinak ovarium yang diikutsertakan dalam penelitian ini. Rerata atau median kadar SOD dan MDA pada penderita keganasan ovarium adalah 1,23 (0,24-5,709) dan 0,803 ± 0,316 , sementara rerata atau median kadar SOD dan MDA pada penderita tumor jinak ovarium adalah 0,488 (0,101-1,86) dan 0,634 ± 0,266. Terdapat perbedaan kadar SOD dan MDA yang bermakna antara kedua kelompok. Terdapat perbedaan kadar SOD yang bermakna antara penderita keganasan ovarium stadium awal dengan penderita keganasan ovarium stadium lanjut. Sementara pada pemeriksaan MDA tidak terdapat perbedaan bermakna antara penderita stadium awal dengan stadium lanjut. Kesimpullan pada penelitian ini terdapat perbedaan kadar SOD dan MDA yang bermakna antara penderita keganasan ovarium dengan penderita tumor jinak ovarium.

---

Ovarian cancer is the leading cause of death due to gynecological malignancies among women. A lot of evidence shows that ovarian cancer is generally influenced by oxidative stress. In this study aims to determine the activity of SOD enzymes and MDA levels in patients with ovarian malignancies and patients with benign ovarian tumors. The study was conducted by cross-sectional tests carried out in the RSCM Jakarta Gynecology Obstetric Room and Persahabatan Hospital Jakarta and Fatmawati Hospital Jakarta in July to December 2018. All patients with ovarian malignancies and patients with benign ovarian tumors who met the criteria were included in this study. Blood from ovarian tumor patients taken before surgery, then the samples were measured for SOD and MDA levels. There were 35 ovarian malignancies and 43 patients with benign ovarian tumors included in the study. The mean or median level of SOD and MDA in patients with ovarian malignancy is 1.23 (0.24 - 5.709) and 0.803 ± 0.316, while the mean or median level of SOD and MDA in patients with benign ovarian tumors is 0.488 (0.101-1.86) and 0.634 ± 0.266. There were significant differences in SOD and MDA levels between the two groups. There were significant differences in SOD levels between patients with early-stage ovarian malignancies and those with advanced ovarian malignancies. While on MDA examination there were no significant differences between patients with early stages with advanced stages. Conclusion in this study were significant differences in SOD and MDA levels between ovarian malignancies and patients with benign ovarian tumors"

"[, Tujuan penelitian adalah untuk membuktikan hipotesabahwa akan didapat kadar asam sia1at yang lebih tinggi pada serum penderita tumor ganas mata dibandingkan dengan kadar asam sia1at pada penderita tumor jinak mata dan orang normal. Dari pene1itian ini diharapkan dapat ditarik suatu kesimpu1an yang dapat membantu penata1aksanaan diagnosa tumor ganas mata.

---

The purpose of the research is to prove the hypothesis that higher levels of sialic acid will be obtained in the serum of patients with malignant tumors of the eye compared to levels of sialic acid in patients with benign tumors of the eye and normal people. From this study, it is hoped that a knowledge can be drawn that can help in the diagnosis of malignant tumors of the eye.]"

"Latar BelakangPeningkatan insiden setiap tahun menjadikan meningioma sebagai salah satu masalah primer tumor jinak sistem saraf pusat (54,5%), dengan karakteristik laju pertumbuhan dan rekurensi tinggi. Maka, diperlukan penetapan rangkaian tatalaksana meningioma yang efektif dan efisien, dengan mempertimbangkan faktor pasien, lokasi tumor, volume, dan riwayat medis.MetodePenelitian menggunakan pendekatan studi potong lintang deskriptif-analitik untuk mengamati luaran radiologis meningioma pasca-GKRS. Digunakan data rekam medis pasien meningioma dari tahun 2018 hingga 2023 berupa MRI follow up satu tahun pasca- GKRS. Selain penyajian data pasien meningioma pasca-GKRS secara deskriptif, dilakukan analisis data laju pertumbuhan meningioma pasca-GKRS terhadap volume awal, lokasi, dan riwayat tindakan pra-GKRS.HasilDari 50 data rekam medis, sebanyak 44% tumor alami regresi; 44% tumor ukuran stabil, dan 12% tumor mengalami peningkatan ukuran. Mayoritas pasien meningioma pasca- GKRS berjenis kelamin perempuan, berusia 46 – 59 tahun, memiliki lokasi tumor supratentorial, volume awal ≤30 cc, dan tanpa riwayat tindakan pra-GKRS. Tidak ditemukan adanya hubungan bermakna antara laju pertumbuhan meningioma pasca- GKRS terhadap volume awal, lokasi, maupun riwayat tindakan pra-GKRS. KesimpulanLaju kontrol pertumbuhan tumor meningioma mencapai efektivitas 88% dalam jangka satu tahun pasca-GKRS. Tidak didapatkan hubungan bermakna antara volume awal, lokasi meningioma, maupun riwayat tindakan pra-GKRS terhadap luaran laju pertumbuhan tumor tertentu.

---

Introduction

Increasing incidence of meningioma every year makes it one of the primary problems of benign tumors of the central nervous system (54.5%), with characteristics of high growth rate and recurrence. Therefore, it is necessary to determine an effective and efficient management of meningioma by considering patient factors, tumor location, volume, and medical history. One of the newest meningioma treatment modalities in Indonesia is Gamma Knife Radiosurgery, a minimally invasive radiation surgery. Although it has been implemented since 2018, there are no studies analyzing the outcomes of Gamma Knife treatment for meningioma patients at RSUPN Dr. Cipto Mangunkusumo.

Method

The study used a descriptive-analytic cross sectional study approach to observe the radiological outcomes of meningioma after Gamma Knife. Medical record data of meningioma patients from 2018 to 2023 in the form of MRI follow-up one year after GKRS was used. In addition to descriptive presentation of Gamma Knife meningioma patient data (age and gender), significance tests of meningioma control rate after Gamma Knife have been analyzed towards the initial volume, location, and medical history prior to GKRS.

Results

Of the 50 medical records, 44% had regression, 44% had stable size, and 12% had increased size. The majority of GKRS meningioma patients were female, aged 46 - 59 years, had supratentorial tumor location, initial volume ≤30 cc, and no history of pre- GKRS treatment. There was no significant relationship between meningioma control rate after GKRS and initial volume, location, or history of pre-GKRS treatment.

Conclusion

The meningioma tumor growth control rate reached 88% effectiveness within one year after Gamma Knife. There was no significant association between initial volume, meningioma location, or history of pre-GKRS treatment on the trend of specific tumor control rate outcomes."